Approximately half of all current clinical gene therapy research is on cancer. To date, there are several hundred projects with some focus on treating cancer with gene therapies. (image credit: Kobizmedia/ Korea Bizwire)
NEW YORK, Feb. 9, 2015 (Korea Bizwire) – A market for gene therapy exceeding $13 billion could be possible by 2025 if the technologies show success in the current trials underway. Gene therapy involves modification of genes instead of using a surgical method or chemical drug product. The healthcare market researcher revealed its finding in The Market for Personalized Gene Therapy Treatments for Cancer.
“Cancer treatment market is slowly showing favor to biotherapies as a whole and gene therapy is expected to make an impact in cancer treatment throughout the coming decade,” said Melissa Elder, analyst for Kalorama Information. ”We think that a portion of the current technologies under development will prove safe and effective although many will also be discontinued and some initially promising projects will be terminated.”
Historically, cancer treatments have been very invasive and detrimental process to the body. However, there are numerous new techniques available for those with cancer that are not as invasive and detrimental to the body as a whole. The report says that Gene therapy is the most prominent new form of these alternative treatments. It is being studied as a way to change how a cell functions, for example, by stimulating the cells of the immune system to attack cancer cells.
Approximately half of all current clinical gene therapy research is on cancer. To date, there are several hundred projects with some focus on treating cancer with gene therapies.
Kalorama points to three recent events that presage positive trends for gene therapy:
- Glybera, from Dutch biotech firm UniQure (QURE.O) and its Italian marketing partner Chiesi has a price tag of 1.4 million dollars.
- Spark Therapeutics’ – The company’s shares opened at $45.10 in their debut on Friday, nearly double their IPO price of $23, and soared to a high of $50 with about 6.6 million shares changing hands. Spark Therapeutics’ most advanced product candidate is in a Phase 3 clinical trial and targets a group of rare blinding conditions.
- U.S. drug giant Pfizer Inc (PFE.N) said last month it is moving into gene therapy.
Kalorama’s report, The Market for Personalized Gene Therapy Treatments for Cancer contains a breakout for market expectations for each type of cancer to the year 2025. It also looks at products in company pipelines. The report is available at http://www.kaloramainformation.com/Personalized-Gene-Therapy-8644345/
About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog at www.kaloramainformation.com.
Source: Kalorama Information (via PR Newswire)
